Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind preventive treatment with allopurinol 3% cream vs placebo for capecitabine-induced hand-foot syndrome
2010-022095-31Phase 2Active
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Erythrodysesthesia syndrome (PPE) and breast cancer comparing Allopurinol 3% cream with Placebo cream (2 arms). Primary endpoint: Prevention of palmar-plantar erythrodysesthesia. Started Sep 2010; status: active.
02
Drugs
allopurinol
03
Conditions
Erythrodysesthesia syndrome (PPE)breast cancer
Beyond the preview
Go deeper on 2010-022095-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022095-31.